Evidence map›Paper›PMID 36959374›Full record

ArticleScientific reports2023

MRI-based long-term follow-up of indolent orbital lymphomas after curative radiotherapy: imaging remission criteria and volumetric regression kinetics.

Christian Hoffmann, Christopher Mohr, Patricia Johansson, Anja Eckstein, Andreas Huettmann, Julia von Tresckow, Sophia Göricke, Cornelius Deuschl, Christoph Poettgen, Thomas Gauler and 5 more

Open access · goldFull text read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Christian HoffmannDepartment of Radiotherapy, University Hospital of Essen, Hufelandstrasse 55, 45147, Essen, Germany. christian.hoffmann2@uk-essen.de.ORCID 0000-0002-5776-439X
Christopher MohrDepartment of Oral and Maxillofacial Surgery, University of Duisburg-Essen, Kliniken-Essen-Mitte, Essen, Germany.
Patricia JohanssonInstitute of Cell Biology (Cancer Research), Faculty of Medicine, University of Duisburg-Essen, Essen, Germany.
Anja EcksteinDepartment of Ophthalmology, University Hospital of Essen, Essen, Germany.
Andreas HuettmannDepartment of Hematology, University Hospital Essen, Essen, Germany.
Julia von TresckowDepartment of Hematology, University Hospital Essen, Essen, Germany.
Sophia GörickeInstitute for Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany.
Cornelius DeuschlInstitute for Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany.
Christoph PoettgenDepartment of Radiotherapy, University Hospital of Essen, Hufelandstrasse 55, 45147, Essen, Germany.
Thomas GaulerDepartment of Radiotherapy, University Hospital of Essen, Hufelandstrasse 55, 45147, Essen, Germany.
Nika GuberinaDepartment of Radiotherapy, University Hospital of Essen, Hufelandstrasse 55, 45147, Essen, Germany.
Sourour MoliaviDepartment of Radiotherapy, University Hospital of Essen, Hufelandstrasse 55, 45147, Essen, Germany.
Nikolaos BechrakisDepartment of Ophthalmology, University Hospital of Essen, Essen, Germany.
Martin StuschkeDepartment of Radiotherapy, University Hospital of Essen, Hufelandstrasse 55, 45147, Essen, Germany.
Maja GuberinaDepartment of Radiotherapy, University Hospital of Essen, Hufelandstrasse 55, 45147, Essen, Germany.
Essen University Hospital · DEKliniken Essen-Mitte · DEUniversity of Duisburg-Essen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We systematically analyzed the kinetics of tumor regression, the impact of residual lesions on disease control and the applicability of the Lugano classification in follow-up MRI of orbital non-Hodgkin lymphomas that were irradiated with photons. We retrospectively analyzed a total of 154 pre- and post-irradiation MRI datasets of 36 patients with low-grade, Ann-Arbor stage I, orbital non-Hodgkin lymphomas. Patients with restricted conjunctival involvement were excluded. Lymphoma lesions were delineated and volumetrically analyzed on T1-weighted sequences. Tumor residues were present in 91.2% of all cases during the first six months after treatment. Volumetric partial response rates (> 50% volume reduction) were 75%, 69.2%, and 50% at 12-24 months, 36-48 months and > 48 months after the end of treatment. The corresponding complete response (CR) rates according to the Lugano classification were 20%, 23.1% and 50%. During a median clinical follow-up of 37 months no significant differences in progression free survival (PFS) rates were observed between the CR and non-CR group (p = 0.915). A residual tumor volume below 20% of the pretreatment volume should be expected at long-term follow-up beyond one year after radiotherapy.

Indexed as

LymphomaLymphoma, Non-HodgkinAntineoplastic Combined Chemotherapy ProtocolsFollow-Up StudiesHumansMagnetic Resonance ImagingRetrospective StudiesTreatment Outcome

Identifiers

PMID36959374
PMCPMC10036339
OpenAlexW4360611356

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read57
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.